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In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen
receptor, two crucial transcription factors in prostate cancer. There is an extraordinary degree of overlap
between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation
and promotes EZH2-mediated dedifferentiation.Theandrogen receptor (AR) plays a critical
role for both normal prostate and for pros-
tate cancer development. AR inhibition
represents the most effective systemic
treatment of prostate cancer and resis-
tance mechanisms predominantly involve
reactivation of AR signaling, such as by
AR overexpression, instead of bypassing
the need for AR (Chen et al., 2004).
Yet, the role of AR in prostate cancer is
complicated. AR regulates transcriptional
programs for both growth and differentia-
tion, and many prototypic AR regulated
genes, such as prostate specific antigen
(PSA), are markers of differentiation. Clini-
cians have long observed that patients
with higher grade prostate cancer tend
to manifest lower PSA relative to disease
volume, and several large-scale gene
expression data sets suggest that these
AR targets are downregulated in both
higher-grade disease and at metastatic
sites. On the other hand, expression of
AR itself tends to increase with higher
grade and is notably higher in castration
resistant metastatic disease (Holzbeier-
lein et al., 2004). These observations
suggest that in prostate cancer, AR may
be co-opted to preferentially regulate
growth genes instead of differentiation
genes. Recent work showing that AR
regulates a distinct set of cell growth
genes in castration-resistant compared
to hormone-sensitive cells highlights
the plasticity of AR (Wang et al., 2009).
What governs AR specificity is a crucial
question.
Tomlins and colleagues made the
seminal discovery that 50% of all pros-tate cancers harbor a fusion between the
androgen-regulated TMPRSS2 gene and
ERG. Three other ETS family transcription
factors, ETV1, ETV4, and ETV5, were
also found fused to various highly ex-
pressed genes in another 10% of pros-
tate cancers. Mouse modeling and tissue
reconstitution assays have confirmed the
oncogenicity of these ETS factors in pros-
tate, particularly in the context of cooper-
ating lesions, such as PTEN loss (King
et al., 2009). Yet, despite intense study,
the mechanisms by which ETS transcrip-
tion factors mediate oncogenesis are
largely unknown.
Gene regulation by ETS transcription
factors is highly complex. There are 27
ETS factors in the human genome, with
many co-expressed within any given cell
type, all characterized by binding to a
short GGA(A/T) core motif found in a
large fraction of promoters. Despite this
apparent redundancy, ETS factors clearly
have unique functions since targeted
deletion of single ETS family members in
mice confers distinct phenotypes. Global
analyses of ETS binding sites in various
tissues suggest the following themes:
(1) multiple ETS factors simultaneously
bind the promoters of many ‘‘house-
keeping’’ genes, but no single ETS factor
significantly regulates these genes; (2)
specific ETS factors bind enhancers of
many tissue-specific genes and regulate
their expression; and (3), most impor-
tantly, ETS factors function in concert
with other transcription factors on cis-
regulatory binding modules. Examples
include coregulation of Ras-responsiveCancer Celelements by ETS and JUN factors,
endothelial specific genes by ETS and
Forkhead factors, erythroid andmegakar-
yocytic specific genes by ETS and GATA
factors, and T cell-specific genes by ETS
and RUNX factors (Hollenhorst et al.,
2009).
Does pathologic expression of ERG in
prostate cancer follow a similar model?
In this issue of Cancer Cell, Yu and
colleagues have taken a first step in
addressing this question by annotating
ERG binding sites in the prostate cancer
genome and find over 42,000 ERG
binding sites mapping to 14,000 genes
(Yu et al., 2010).While it may seem incred-
ible that ERG maps to nearly half of all
known genes, this number is consistent
with recent ChIP-Seq studies of ETS
family proteins in other tissues. In a
parallel analysis, Yu et al. report 13,000
AR binding sites mapping to over 6,000
genes, with an extraordinary degree of
overlap between AR and ERG binding
sites, particularly in enhancer regions.
This finding confirms the prediction of an
earlier study that showed enrichment of
ETS motifs adjacent to AR binding sites
(Massie et al., 2007). Collectively, these
data strongly suggest that ERG and AR
cooperate at cis-regulatory elements to
drive gene expression in TMPRSS2-ERG
positive cancers (Figure 1). But unlike
the established models of ETS coopera-
tivity in normal tissues listed above, ERG
is not expressed in the normal prostate
and presumably activates an aberrant
transcription program, perhaps by per-
turbing the normal AR network.l 17, May 18, 2010 ª2010 Elsevier Inc. 415
Figure 1. Coordinate Regulation of Target Genes by Androgen Receptor and ERG
AR binding at enhancers of AR target gene causes looping and gene activation. The ‘‘GGAA’’ ETS motif is
highly enriched at AR binding sites, raising the possibility that an unidentified ETS protein (not ERG) may
coordinately regulate transcription in normal prostate cells (top). In ERG-positive prostate cancer, ERG
now localizes at these sites, perhaps displacing an ‘‘endogenous’’ ETS factor, as well as gene promoters,
and inhibits AR mediates transcriptional activation.
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gation and, surprisingly, find that ERG
suppresses AR function, through a
decrease in AR levels (ERG-mediated
transcriptional suppression of AR) as
well as inhibition of AR transcriptional
activity on canonical target genes. At first
glance, this result seems paradoxical.
AR activation is central to prostate cancer
progression, even at the castration-resis-
tant stage based on recent clinical suc-
cess of next generation AR pathway
antagonists such as abiraterone and
MDV3100 (Scher et al., 2010). Further,
expression of the oncogenic ERG fusion
protein is controlled by the AR-dependent
gene TMPRSS2; hence, ERG could extin-
guish its own expression! This is clearly
not the case in human tumors; therefore,
ERG and AR must function in a negative
autoregulatory loop tightly controlling
levels of both transcription factors. Too
much AR activity increases ERG protein
through TMPRSS2 regulatory regions,
which turns down AR and ERG and vice
versa. Another possibility is that ERG
shifts the balance of AR target gene regu-
lation to those that primarily drive growth
rather than differentiation programs.
While intriguing, more work is needed
to clarify certain aspects of the model.
Others have recently shown that the other
ETS family fusion partner ETV1 also binds
the PSA enhancer cooperatively with416 Cancer Cell 17, May 18, 2010 ª2010 ElsAR but exerts the opposite effect—an
increase in AR target gene expression
(Shin et al., 2009). Since ETV1 and ERG
appear to have similar functions in pros-
tate oncogenesis, it is difficult to reconcile
opposing effects on AR output as central
to their transforming activity. Indeed,
the AR target genes downregulated by
ERG, such as PSA, are markers of differ-
entiation but there is little evidence to
suggest that they are mediators of differ-
entiation. More detailed characterization
of AR target genes across a larger panel
of ERG- and ETV1-positive cancers is
required to fully flesh out the model.
In addition, recent studies of nuclear
receptor (NR) cistromes reveal cell-type
specificity defined in part by ‘‘pioneer’’
transcription factors such as FOXA1 that
bind in advance and modify chromatin
for optimal NR binding (Lupien et al.,
2008). Since AR expression almost cer-
tainly precedes ERG expression in fusion-
positive prostate cancers, ERG is unlikely
to pioneer AR binding but the relationship
between the two needs further dissection,
i.e., do they bind independently? Cooper-
atively? Does dual binding substantially
alter chromatin landscape?
The authors also implicate the histone
methyltransferase and polycomb group
protein EZH2 as another ERG target
gene independent of effects on AR. ERG
binds to the EZH2 promoter and inducesevier Inc.expression. This result is compelling
since EZH2 was recently shown to
enhance metastasis in an orthotopic
prostate cancer model (Min et al., 2010).
EZH2 overexpression is correlated with
increased tumor grade in many tumor
types and may reflect a state of dediffer-
entiation. Whether EZH2 upregulation in
prostate cancer is exclusively linked to
ERG fusion positive cancers requires
further study. Taken together, this study
unambiguously links AR and ERG as
coregulators of prostate cancer gene
expression and proposes new models
of prostate cancer progression. In light
of this work, further characterization of
ERG and AR signaling in murine models
and human samples will be of great
interest.REFERENCES
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